Trial reportWorld journal of gastroenterology2025
Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch.
Trial report in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- [Effect of switching from entecavir to tenofovir amibufenamide on HBsAg levels in patients with chronic hepatitis B: a 96-week real-world study].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Article
- Pradefovir mesylate and tenofovir amibufenamide for chronic hepatitis B: a systematic review and pragmatic treatment algorithm.Frontiers in pharmacology · 2026Review
- Real-world effectiveness and safety of tenofovir amibufenamide in treatment-naïve chronic hepatitis B: a 48-week retrospective cohort study.Frontiers in medicine · 2026Article
- Efficacy and Cost-Effectiveness Analyses of Entecavir versus Tenofovir Amibufenamide in Patients with Chronic Hepatitis B.Drug design, development and therapy · 2026Article
- Effectiveness and safety of tenofovir alafenamide in chronic hepatitis B patients over 30 years old with positive hepatitis B virus DNA: a double-center retrospective study.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTenofovir amibufenamide (TMF) has shown antiviral efficacy comparable to tenofovir disoproxil fumarate (TDF) in chronic hepatitis B (CHB), with improved renal and bone safety profiles. While TDF is recognized for its lipid-lowering properties, the long-term effects of TMF on lipid metabolism remain unclear.
aimTo assess lipid changes and long-term safety of TMF in CHB, including outcomes after TDF-to-TMF switch over 144 weeks.
methodsThis retrospective analysis utilized data from a phase III randomized, double-blind trial involving 53 patients with CHB treated with either TMF 25 mg (
resultsAt week 96, both groups achieved comparable virological suppression and maintained stable hepatic and renal function. However, total cholesterol and low-density lipoprotein cholesterol levels were significantly higher in the TMF group compared to the TDF group (
conclusionTMF provides sustained antiviral efficacy and maintains a favourable long-term lipid and renal safety profile. These findings support TMF as a viable first-line therapy and a switch option for CHB management in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.